vs
ASGN Inc（ASGN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
ASGN Inc的季度营收约是Revvity的1.3倍（$970.0M vs $772.1M），Revvity净利率更高（12.7% vs 0.6%，领先12.2%），Revvity同比增速更快（5.9% vs -3.0%），Revvity自由现金流更多（$161.8M vs $9.1M），过去两年Revvity的营收复合增速更高（9.0% vs -3.2%）
ASGN Inc是总部位于美国的领先专业服务与人力资源解决方案供应商，主营信息技术、创意设计、生命科学、工程等领域的技术人才供给及咨询服务，主要服务北美地区的企业级客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ASGN vs RVTY — 直观对比
营收规模更大
ASGN
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出8.9%
-3.0%
净利率更高
RVTY
高出12.2%
0.6%
自由现金流更多
RVTY
多$152.7M
$9.1M
两年增速更快
RVTY
近两年复合增速
-3.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $970.0M | $772.1M |
| 净利润 | $5.5M | $98.4M |
| 毛利率 | 27.5% | — |
| 营业利润率 | 2.9% | 14.5% |
| 净利率 | 0.6% | 12.7% |
| 营收同比 | -3.0% | 5.9% |
| 净利润同比 | -73.7% | 3.9% |
| 每股收益（稀释后） | $0.13 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASGNRVTY
| Q1 26 | $970.0M | — | ||
| Q4 25 | $980.1M | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $968.3M | $664.8M | ||
| Q4 24 | $985.0M | $729.4M | ||
| Q3 24 | $1.0B | $684.0M | ||
| Q2 24 | $1.0B | $691.7M |
净利润ASGNRVTY
| Q1 26 | $5.5M | — | ||
| Q4 25 | $25.2M | $98.4M | ||
| Q3 25 | $38.1M | $46.7M | ||
| Q2 25 | $29.3M | $53.9M | ||
| Q1 25 | $20.9M | $42.2M | ||
| Q4 24 | $42.4M | $94.6M | ||
| Q3 24 | $47.5M | $94.4M | ||
| Q2 24 | $47.2M | $55.4M |
毛利率ASGNRVTY
| Q1 26 | 27.5% | — | ||
| Q4 25 | 28.9% | — | ||
| Q3 25 | 29.4% | 53.6% | ||
| Q2 25 | 28.7% | 54.5% | ||
| Q1 25 | 28.4% | 56.5% | ||
| Q4 24 | 29.0% | — | ||
| Q3 24 | 29.1% | 56.3% | ||
| Q2 24 | 29.1% | 55.7% |
营业利润率ASGNRVTY
| Q1 26 | 2.9% | — | ||
| Q4 25 | 5.7% | 14.5% | ||
| Q3 25 | 6.7% | 11.7% | ||
| Q2 25 | 5.8% | 12.6% | ||
| Q1 25 | 4.8% | 10.9% | ||
| Q4 24 | 7.5% | 16.3% | ||
| Q3 24 | 7.7% | 14.3% | ||
| Q2 24 | 7.8% | 12.4% |
净利率ASGNRVTY
| Q1 26 | 0.6% | — | ||
| Q4 25 | 2.6% | 12.7% | ||
| Q3 25 | 3.8% | 6.7% | ||
| Q2 25 | 2.9% | 7.5% | ||
| Q1 25 | 2.2% | 6.4% | ||
| Q4 24 | 4.3% | 13.0% | ||
| Q3 24 | 4.6% | 13.8% | ||
| Q2 24 | 4.6% | 8.0% |
每股收益（稀释后）ASGNRVTY
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.58 | $0.86 | ||
| Q3 25 | $0.87 | $0.40 | ||
| Q2 25 | $0.67 | $0.46 | ||
| Q1 25 | $0.48 | $0.35 | ||
| Q4 24 | $0.94 | $0.77 | ||
| Q3 24 | $1.06 | $0.77 | ||
| Q2 24 | $1.02 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $143.6M | $919.9M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $1.8B | $7.3B |
| 总资产 | $4.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.82× | — |
8季度趋势，按日历期对齐
现金及短期投资ASGNRVTY
| Q1 26 | $143.6M | — | ||
| Q4 25 | $161.2M | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $205.2M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
总债务ASGNRVTY
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — |
股东权益ASGNRVTY
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $7.3B | ||
| Q3 25 | $1.8B | $7.4B | ||
| Q2 25 | $1.8B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.8B | $7.7B | ||
| Q3 24 | $1.8B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B |
总资产ASGNRVTY
| Q1 26 | $4.0B | — | ||
| Q4 25 | $3.7B | $12.2B | ||
| Q3 25 | $3.7B | $12.1B | ||
| Q2 25 | $3.7B | $12.4B | ||
| Q1 25 | $3.7B | $12.4B | ||
| Q4 24 | $3.4B | $12.4B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.5B | $13.4B |
负债/权益比ASGNRVTY
| Q1 26 | 0.82× | — | ||
| Q4 25 | 0.65× | — | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.58× | — | ||
| Q3 24 | 0.58× | — | ||
| Q2 24 | 0.57× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $9.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 0.9% | 21.0% |
| 资本支出强度资本支出/营收 | 1.0% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $290.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ASGNRVTY
| Q1 26 | — | — | ||
| Q4 25 | $102.3M | $182.0M | ||
| Q3 25 | $83.9M | $138.5M | ||
| Q2 25 | $124.9M | $134.3M | ||
| Q1 25 | $16.8M | $128.2M | ||
| Q4 24 | $100.2M | $174.2M | ||
| Q3 24 | $135.8M | $147.9M | ||
| Q2 24 | $90.7M | $158.6M |
自由现金流ASGNRVTY
| Q1 26 | $9.1M | — | ||
| Q4 25 | $93.7M | $161.8M | ||
| Q3 25 | $72.0M | $120.0M | ||
| Q2 25 | $115.8M | $115.5M | ||
| Q1 25 | $6.6M | $112.2M | ||
| Q4 24 | $88.9M | $149.8M | ||
| Q3 24 | $127.9M | $125.6M | ||
| Q2 24 | $85.4M | $136.6M |
自由现金流率ASGNRVTY
| Q1 26 | 0.9% | — | ||
| Q4 25 | 9.6% | 21.0% | ||
| Q3 25 | 7.1% | 17.2% | ||
| Q2 25 | 11.3% | 16.0% | ||
| Q1 25 | 0.7% | 16.9% | ||
| Q4 24 | 9.0% | 20.5% | ||
| Q3 24 | 12.4% | 18.4% | ||
| Q2 24 | 8.3% | 19.7% |
资本支出强度ASGNRVTY
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | 2.6% | ||
| Q3 25 | 1.2% | 2.6% | ||
| Q2 25 | 0.9% | 2.6% | ||
| Q1 25 | 1.1% | 2.4% | ||
| Q4 24 | 1.1% | 3.4% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 0.5% | 3.2% |
现金转化率ASGNRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 1.85× | ||
| Q3 25 | 2.20× | 2.97× | ||
| Q2 25 | 4.26× | 2.49× | ||
| Q1 25 | 0.80× | 3.03× | ||
| Q4 24 | 2.36× | 1.84× | ||
| Q3 24 | 2.86× | 1.57× | ||
| Q2 24 | 1.92× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASGN
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
